Literature DB >> 18430998

Colostrinin: an oxidative stress modulator for prevention and treatment of age-related disorders.

Istvan Boldogh1, Marian L Kruzel.   

Abstract

Colostrum-derived proline-rich polypeptide, also known as Colostrinin (CLN), has been shown to have a stabilizing effect on cognitive function in Alzheimer's disease patients. This complex action of CLN could be related to prevention of amyloid-beta peptide aggregation, as shown in in vitro studies, and its impact on delicate cassettes of signaling pathways common to cellular redox regulation, proliferation and differentiation. Studies on cultured cells showed that CLN modulates intracellular levels of reactive oxygen species (ROS), via regulation of glutathione metabolism, activity of antioxidant enzymes and mitochondria function. Due to an improvement in senescence-associated mitochondrial dysfunction and a decrease in ROS generation, CLN decelerates the aging processes of both cultured cells and experimental animals. When given orally to mice, CLN increased the lifespan and improved various motor and sensory activities. Although the molecular basis by which CLN exerts its diverse effects are still under investigation, the regulatory effect on the cellular redox state via maintenance of mitochondrial function and modification of ROS-induced cell signaling seem to be of great importance. In this article, we examine experimental data pertinent to the mechanism of action, including a review of CLN's utility in the maintenance of physiological processes in which oxidative stress has an etiological role.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430998     DOI: 10.3233/jad-2008-13308

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  9 in total

1.  New insight into mode of action of Colostrinin.

Authors:  Michael G Stewart
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

2.  New insights into clinical trial for Colostrinin in Alzheimer's disease.

Authors:  P Szaniszlo; P German; G Hajas; D N Saenz; M Kruzel; I Boldogh
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  Cryptotanshinione inhibits β-amyloid aggregation and protects damage from β-amyloid in SH-SY5Y cells.

Authors:  Zhengrong Mei; Pengke Yan; Bing Situ; Yonggao Mou; Peiqing Liu
Journal:  Neurochem Res       Date:  2011-11-19       Impact factor: 3.996

4.  Neuroprotective and antioxidative effect of cactus polysaccharides in vivo and in vitro.

Authors:  Xianju Huang; Qin Li; Huige Li; Lianjun Guo
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

5.  DADS Analogues Ameliorated the Cognitive Impairments of Alzheimer-Like Rat Model Induced by Scopolamine.

Authors:  Apra Manral; Poonam Meena; Vikas Saini; Fouzia Siraj; Shruti Shalini; Manisha Tiwari
Journal:  Neurotox Res       Date:  2016-05-05       Impact factor: 3.911

6.  C-terminal peptide of γ-enolase impairs amyloid-β-induced apoptosis through p75(NTR) signaling.

Authors:  Anja Hafner Pišlar; Janko Kos
Journal:  Neuromolecular Med       Date:  2013-07-11       Impact factor: 3.843

7.  Neuroprotective effect of single-wall carbon nanotubes with built-in peroxidase-like activity against β-amyloid-induced neurotoxicity.

Authors:  Jaeha Shin; Sujin Lee; Misun Cha
Journal:  Medchemcomm       Date:  2017-02-02       Impact factor: 3.597

Review 8.  Breast Milk: A Source of Functional Compounds with Potential Application in Nutrition and Therapy.

Authors:  Cristina Sánchez; Luis Franco; Patricia Regal; Alexandre Lamas; Alberto Cepeda; Cristina Fente
Journal:  Nutrients       Date:  2021-03-22       Impact factor: 5.717

9.  Pro-Cognitive Properties of the Immunomodulatory Polypeptide Complex, Yolkin, from Chicken Egg Yolk and Colostrum-Derived Substances: Analyses Based on Animal Model of Age-Related Cognitive Deficits.

Authors:  Marta Lemieszewska; Marta Jakubik-Witkowska; Bartłomiej Stańczykiewicz; Aleksandra Zambrowicz; Agnieszka Zabłocka; Antoni Polanowski; Tadeusz Trziszka; Joanna Rymaszewska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-03-14       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.